E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 5/1/2006 in the Prospect News Biotech Daily.

Flamel stays at neutral rating by Merrill

Flamel Technologies' neutral rating remains unchanged by Merrill Lynch analyst Hari Sambasivam as the company prepares to report its first-quarter financial results. Merrill estimates for the quarter include total revenues of $5.5 million, compared with $8.1 million in the first-quarter 2005, and a net loss of $9.6 million, or $0.40 per share, compared with net income of $0.2 million, or $0.01 per share, for the same period last year. Consensus loss per share for the quarter is $0.31. Shares of the Venissieux, France, biopharmaceutical company were down 14 cents, or 0.69%, at $20.06 on volume of 116,081 shares versus the three-month running average of 150,035 shares. (Nasdaq: FLML)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.